Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy

Chen, Guojun; Chen, Zhitong; Wen, Di; Wang, Zejun; Zhang, Dongliang; Zeng, Yi Xin; Dotti, Gianpietro; Wirz, Richard E.; Gu, Zhen

doi:10.1073/pnas.1917891117

Cited by 184 publications

(138 citation statements)

References 35 publications

(30 reference statements)

Supporting

Mentioning

131

Contrasting

Order By: Relevance

“…Numerous research groups are attempting to investigate and utilize these selective mechanisms of action for biomedical applications. Exemplary mention should be made here of the work of Xu et al [9] on the influence of plasma-generated radicals on the structural modification of gap junctions and the research of Chen et al [10] on CAP-mediated immune checkpoint blockade therapy in a transdermal approach.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Risk Assessment for Medical Application of Cold Atmospheric Pressure Plasma

et al. 2020

View full text Add to dashboard Cite

Despite increasing knowledge gained based on multidisciplinary research, plasma medicine still raises various questions regarding specific effects as well as potential risks. With regard to significant statements about in vivo applicability that cannot be prognosticated exclusively based on in vitro data, there is still a deficit of clinical data. This study included a clinical follow-up of five probands who had participated five years previously in a study on the influence of cold atmospheric pressure plasma (CAP) on the wound healing of CO2 laser-induced skin lesions. The follow-up included a complex imaging diagnostic involving dermatoscopy, confocal laser scanning microscopy (CLSM) and hyperspectral imaging (HSI). Hyperspectral analysis showed no relevant microcirculatory differences between plasma-treated and non-plasma-treated areas. In summary of all the findings, no malignant changes, inflammatory reactions or pathological changes in cell architecture could be detected in the plasma-treated areas. These unique in vivo long-term data contribute to a further increase in knowledge about important safety aspects in regenerative plasma medicine. However, to confirm these findings and secure indication-specific dose recommendations, further clinical studies are required.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-Term Risk Assessment for Medical Application of Cold Atmospheric Pressure Plasma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Anti-programmed death-ligand 1 antibody (aPDL1), an immune checkpoint inhibitor, released from the MN patch further augmented antitumour immunity. Their findings indicate that the proposed transdermal combined CAP and ICB therapy can inhibit the tumour growth of both primary tumours and distant tumours, prolonging the survival of tumour-bearing mice [89].…”

Section: Immunotherapy and Capmentioning

confidence: 95%

“…Recently studied plasma-related immunogenic effects include the use of CAP-mediated immune checkpoint blockade (ICB) therapy integrated with microneedles (MN), described for the transdermal delivery of ICB by Chen et al (2020) [89]. They found that a hollow-structured MN (hMN) patch facilitated the transportation of CAP through the skin, causing tumour cell death.…”

Section: Immunotherapy and Capmentioning

confidence: 99%

“…The clinical importance of such reviews is now emerging, and plasma medical devices are widely used in current practice, such as the plasma jet kINPen or InvivoPen [87,88]. The benefits of CAP in clinical application are increasing, most recently in immunotherapy [89,90], and in the combination of CAP and nanoparticles [27,40,91]. CAP thus seems to be an auspicious tool for the development of a new cancer treatment strategy in vulva oncology.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology

Žúbor

Wang

Líšková

et al. 2020

IJMS

View full text Add to dashboard Cite

Vulvar cancer (VC) is a specific form of malignancy accounting for 5–6% of all gynaecologic malignancies. Although VC occurs most commonly in women after 60 years of age, disease incidence has risen progressively in premenopausal women in recent decades. VC demonstrates particular features requiring well-adapted therapeutic approaches to avoid potential treatment-related complications. Significant improvements in disease-free survival and overall survival rates for patients diagnosed with post-stage I disease have been achieved by implementing a combination therapy consisting of radical surgical resection, systemic chemotherapy and/or radiotherapy. Achieving local control remains challenging. However, mostly due to specific anatomical conditions, the need for comprehensive surgical reconstruction and frequent post-operative healing complications. Novel therapeutic tools better adapted to VC particularities are essential for improving individual outcomes. To this end, cold atmospheric plasma (CAP) treatment is a promising option for VC, and is particularly appropriate for the local treatment of dysplastic lesions, early intraepithelial cancer, and invasive tumours. In addition, CAP also helps reduce inflammatory complications and improve wound healing. The application of CAP may realise either directly or indirectly utilising nanoparticle technologies. CAP has demonstrated remarkable treatment benefits for several malignant conditions, and has created new medical fields, such as “plasma medicine” and “plasma oncology”. This article highlights the benefits of CAP for the treatment of VC, VC pre-stages, and postsurgical wound complications. There has not yet been a published report of CAP on vulvar cancer cells, and so this review summarises the progress made in gynaecological oncology and in other cancers, and promotes an important, understudied area for future research. The paradigm shift from reactive to predictive, preventive and personalised medical approaches in overall VC management is also considered.

show abstract

“…17 CAP treatment promotes dendritic cell (DC) maturation in the lymph node, where DCs can present the major histocompatibility complexpeptide to T cells. 18 The subsequent T cell-mediated immune response can be augmented by the immune checkpoint inhibitors, resulting in enhanced local and systemic antiviral immunity. The adoptive therapy of CAP should be an ideal choice to be employed or combined with other immune modulating agents for COVID-19.…”

mentioning

confidence: 99%

Cold Atmospheric Plasma for COVID-19

Chen¹,

Wirz²

2020

Preprint

Self Cite

View full text Add to dashboard Cite

The recent pandemic has greatly stressed supply chains, treatment modalities, and medical resources. Cold atmospheric plasma (CAP) has been used for a wide range of applications in biomedical engineering due to its many components including electrons, charged particles, reactive oxygen species (ROS), reactive nitrogen species (RNS), free radicals, ultraviolet (UV) photons, molecules, electromagnetic fields, physical forces, and electric fields. In this manuscript, we develop CAP devices for COVID-19. Our manuscript indicates the advantages of highlydeployable CAP devices for both sanitation and treatment, without the need for supply chains of special consumables such as hand sanitizers and the like. We hope that this timely research will help engage the broader community of engineers that wish to help the medical community with this pandemic and to prevent and treat future outbreaks.Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 8 April 2020

show abstract

Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy

Cited by 184 publications

References 35 publications

Long-Term Risk Assessment for Medical Application of Cold Atmospheric Pressure Plasma

Long-Term Risk Assessment for Medical Application of Cold Atmospheric Pressure Plasma

Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology

Cold Atmospheric Plasma for COVID-19

Contact Info

Product

Resources

About